Daniel O'Leary

Daniel O'Leary, MD is an Assistant Professor of Medicine within the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School. His clinical and research activities focus on advancing treatments for hematologic malignancies through cellular therapies and transplantation protocols.

Dr. O'Leary's research spans hematologic oncology with emphasis on CAR-T cell therapy for multiple myeloma, allogeneic stem cell transplantation for cutaneous lymphomas, and biomarker-driven outcome prediction. His work addresses critical challenges including graft-versus-host disease prevention, neurotoxicity management in immunotherapy, and optimizing transplant conditioning regimens for diverse patient populations. He employs methodologies ranging from multi-institutional clinical trials to systematic reviews of rare lymphoma subtypes.

Analysis of his 2022-2025 publications reveals dominant trends in cellular immunotherapy and transplantation medicine. Key themes include biomarker validation (e.g., eosinophil counts predicting CAR-T outcomes), development of reduced-toxicity transplant protocols using post-cyclophosphamide regimens, and clinical guideline creation for rare lymphomas like mycosis fungoides. His research frequently involves large-scale population studies and systematic meta-analyses to address evidence gaps in hematologic malignancy management.

Dr. O'Leary has contributed to national clinical practice standards including ASTCT/USCLC guidelines for stem cell transplantation in cutaneous T-cell lymphomas. His collaborative work appears in high-impact hematology journals with consistent focus on improving real-world patient outcomes through protocol standardization.

No scientific awards were documented in the available source materials.

Information regarding student mentorship and specific research grants was not provided in the source documentation, though his publication record indicates active participation in multi-center clinical trials and systematic review consortia.

As a member of the Division of Hematology, Oncology and Transplantation, Dr. O'Leary contributes to a multidisciplinary team conducting translational research in cellular therapies, with particular focus on expanding access to novel immunotherapies for hematologic malignancy patients.